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Abstract
Objective: The objective of this article is to review the prospect of treating migraine with sphenopalatine ganglion (SPG)
neurostimulation.
Background: Fuelled by preliminary studies showing a beneficial effect in cluster headache patients, the potential of
treating migraine with neurostimulation has gained increasing interest within recent years, as current treatment strate-
gies often fail to provide adequate relief from this debilitating headache.
Common migraine symptoms include lacrimation, nasal congestion, and conjunctival injection, all parasympathetic
manifestations. In addition, studies have suggested that parasympathetic activity may also contribute to the pain of
migraineurs.
The SPG is the largest extracranial parasympathetic ganglion of the head, innervating the meninges, lacrimal gland,
nasal mucosa, and conjunctiva, all structures involved in migraine with cephalic autonomic symptoms.
Conclusion: We propose two possible mechanisms of action: 1) interrupting the post-ganglionic parasympathetic outflow
to inhibit the pain and cephalic autonomic symptoms, and 2) modulating the sensory processing in the trigeminal nucleus
caudalis. To further explore SPG stimulation in migraineurs as regards therapeutic potential and mode of action,
randomized clinical trials are warranted.
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Introduction
Migraine is a common neurological syndrome, rated as
one of the most severe disabling disorders by the World
Health Organization (1). It is managed pharmacologic-
ally with acute and preventive drug therapies. However,
current treatment strategies are often suboptimal in
terms of inadequate eﬃcacy and substantial side eﬀects
(2). New treatment modalities are therefore warranted
to better fulﬁll the therapeutic needs of migraineurs,
especially patients suﬀering from severe and frequent
migraine.
There is a growing interest in neuromodulation as a
treatment for primary headache disorders. Applying
electrical stimulation to relieve pain syndromes is no
new approach, but within recent years devices and
stimulation protocols have become more accurate
and less invasive. While neuromodulation was previ-
ously limited to drug-refractory patients, it is now
increasingly applied as an alternative to acute and
prophylactic therapy (2), raising the question whether it
can serve as a valid option in the treatment of migraine.
In addition to the diagnostic criteria speciﬁed by
the International Headache Society (1), migraine can
be associated with cranial autonomic symptoms
(CAS) of lacrimation, conjunctival injection, eyelid
edema, nasal congestion, and forehead/facial sweating
(3,4) in 27% to 73% of cases depending on criteria
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and study design (3–6). This correlation is not limited
to adults but also includes migraineurs under the age
of 18 years, with a recent study showing 62% of chil-
dren and adolescents complaining of migraine-asso-
ciated CAS (7). The presence of CAS in migraineurs
suggests activation of the trigemino-autonomic reﬂex
resulting in increased parasympathetic outﬂow (8), as
in the trigeminal autonomic cephalalgias (including
cluster headache (CH), chronic paroxysmal hemicra-
nias and short-lasting unilateral neuralgiform head-
ache attacks with conjunctival injection and tearing
(SUNCT)). In the latter headache group, clinicians
have long attempted to treat attacks and associated
symptoms by targeting the sphenopalatine ganglion
(SPG), a procedure ﬁrst introduced at the beginning
of the 20th century by Sluder to treat so-called
Sluder’s neuralgia, a type of trigeminal autonomic
cephalalgia (9). Besides pharmacological blocks, SPG
interventions have since included surgical or radiofre-
quency ablations, radiosurgical targeting or lesions
(10–13). As the SPG is the major source of parasym-
pathetic innervation not only to the face but also to
the cranial cavity, SPG activation could also be a
likely contributor to migraine pathophysiology.
A multicenter study (Pathway M1: Sphenopalatine
Ganglion Stimulation for the Treatment of Chronic or
High Frequency, High-Disability Migraine Headache)
is currently under way, a randomized, controlled,
interventional, prospective study to evaluate the use
of an implanted SPG neurostimulator for the treat-
ment of migraine headache pain, migraine headache
symptoms and migraine frequency in high-disability
migraineurs (clinicaltrial.gov: NCT01540799). Inclu-
sion criteria comprise subjects reporting at least 75%
of migraine attacks to be ﬁxed unilateral, preferably
with associated CAS.
This review will focus on the SPG as a possible target
for treating migraine. We will describe the pathophysi-
ology of migraine, concentrating on a parasympathetic
dysfunction and the possible role of a hypothalamo-
parasympathetico-trigeminal triangle. In addition,
we will discuss the possible rationale for
potential therapeutic eﬀects of SPG neurostimulation
in migraine.
Methods
Search strategy and selection criteria
We searched PubMed for publications on SPG’s inﬂu-
ence on migraine, ultimately selecting articles from the
period 1908–2013. The keywords were ‘‘sphenopalatine
ganglion,’’ ‘‘migraine,’’ ‘‘trigeminovascular pathway,’’
‘‘trigeminal-parasympathetic reﬂex,’’ ‘‘neuromodu-
lation,’’ and ‘‘neurostimulation.’’ The search was lim-
ited to English language publications and resulting
articles were reviewed based on their abstracts to
include only pertinent publications, dealing speciﬁcally
with CAS in migraineurs, anatomical and functional
connections between the SPG, cerebral vessels, trigemi-
novascular system and hypothalamus, and possible
therapeutic prospects of SPG neurostimulation.
Anatomo-functional characteristics
of the SPG and the trigemino-
parasympathetic reflex
The SPG is the largest extracranial parasympathetic
ganglion (Figure 1), with sensory and sympathetic
ﬁbers also projecting through the ganglion, however,
without synapsing. The parasympathetic ﬁbers origin-
ate in the superior salivatory nucleus (SSN) of the pons
and supply extra- and intracerebral arteries (14–16), the
lacrimal gland (17,18), nasal mucosa (19,20), conjunc-
tiva (20), and Mu¨ller’s muscle in the upper eyelid (21).
Sympathetic ﬁbers originate in the internal carotid
plexus to innervate the lacrimal gland, nasal, and pal-
atine mucosa (22). The sensory root originates in the
maxillary nerve, supplying the nose, palate, tonsil, and
gingiva (22).
Physiologically, low-frequency electrical stimulation
of the SPG (10–20Hz) in animal studies has revealed
dilation of intra- and extracranial arteries, increased
cerebral blood ﬂow (CBF), and plasma protein extrava-
sation (PPE) in the dura mater (Table 1). PPE is
mediated by sensory neurons that contain potent
vasodilator neurotransmitters such as calcitonin gene-
related peptide (CGRP), substance P (SP), and neuro-
kinin A (NA) (23). As PPE may activate meningeal
nociceptors to induce the headache of migraine via
neurogenic inﬂammation (23,24) and dilation of intra-
and extracranial arteries is related to migraine attacks
(25–27), these eﬀects of SPG stimulation contribute to
the pathophysiologic understanding of migraine while
introducing the prospect of targeting the ganglion with
high-frequency stimulation (100Hz) for treatment
purposes.
The trigemino-parasympathetic reﬂex consists of a
brainstem connection between trigeminal aﬀerents
and parasympathetic eﬀerents of the facial nerve that
synapse in the SPG (8,34,35). The reﬂex has been
broadly demonstrated in animal and human studies,
showing that trigeminal ganglion stimulation leads to
intra- and extracranial vasodilation (36–38), increased
regional CBF (39,40), and increased facial temperature,
a response that is abolished by lesioning the facial nerve
(41). Furthermore, painful stimulation of the ophthal-
mic nerve innervation area results in internal carotid
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artery dilation, CAS, as well as increased ipsilateral
blood ﬂow and lacrimal response, of which the latter
two eﬀects are also inhibited by facialis lesioning
(38,42–44).
Migraine and the parasympathetic
nervous system
Involvement of the autonomic nervous system (ANS)
in migraine is considered likely given the symptoms
commonly associated with attacks; nausea, emesis, con-
junctival injection, lacrimation, nasal congestion, rhi-
norrhea, salivation, diarrhea, and polyuria (45).
Though an alleged autonomic dysfunction has been
dealt with widely, migraine pathophysiology is com-
plex, and results have advocated both hypo- and hyper-
function of the sympathetic and parasympathetic
systems (Table 2) (46–54).
Involvement of speciﬁcally the parasympathetic ner-
vous system is considered plausible as 1) CAS such as
lacrimation, rhinorrhea, and eyelid edema are parasym-
pathetic manifestations (55), 2) levels of vasoactive
intestinal polypeptide (VIP) are elevated in cranial
venous blood during attacks in patients with symptoms
of lacrimation and rhinorrhea (56), 3) meningeal blood
vessels receive dense parasympathetic innervation, 4)
preganglionic parasympathetic neurons in SSN increase
their activity after activation of meningeal nociceptors
(57,58), and 5) intranasal application of lidocaine,
which may block the SPG, is shown to abort migraine
within 15minutes in 36% of patients in a studied popu-
lation (11). These latter results should be taken with
caution as the eﬀect may be due to blockade of the
trigeminovascular aﬀerents passing near the ganglion
rather than blockade of the parasympathetic ﬁbers
(45). However, Yarnitsky et al. (59) interestingly sug-
gested that SPG might not only play a role in mediating
the CAS of migraine but may also contribute to the
pain. This is based on their observations that patients
with parasympathetic symptoms were more likely to
experience pain relief by lidocaine than patients without
parasympathetic symptoms, with a pain reduction of
53% and 15%, respectively.
Avnon et al. (46) studied the trigemino-
parasympathetic reﬂex in migraineurs interictally by
instilling soapy eye drops to activate the aﬀerent limb,
then measuring subsequent cutaneous vascular and
systemic cardiovascular responses as a marker of para-
sympathetic activity. The authors concluded that auto-
nomic dysfunction in migraine exhibits laterality with
parasympathetic hyperfunction in left-sided migrain-
eurs. This concept of asymmetric cerebral function
has been suggested previously in studies on the auto-
nomic control of the heart, where the left hemisphere






















Figure 1. Anatomy of the sphenopalatine ganglion (SPG) and associated structures. The SPG is triangular shaped, located in the
pterygopalatine fossa, and suspended from the maxillary nerve via the two pterygopalatine nerves. Posteriorly, it is connected to the
Vidian nerve formed by the greater petrosal and the deep petrosal nerves. Efferent branches from the ganglion include the superior
posterior lateral nasal, nasopalatine, greater and lesser palatine, and pharyngeal nerves. Caudally the ganglion is in direct connection
with the greater and lesser palatine nerves.
Source: Reprinted with permission, Cleveland Clinic Center for Medical Art & Photography  2005–2013. All rights reserved.































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































was found to predominantly aﬀect parasympathetic
function while the right hemisphere aﬀects sympathetic
function (60–63).
Collectively, these data suggest that ANS plays an
important role in migraine pathogenesis, where
the SPG in particular may mediate parasympathetic
hyperactivity considering the eﬀerent ﬁbers, neuro-
transmitter, and innervation organs of the ganglion
(14–16,18–20).
SPG and the migraine pathway:
A rationale for aborting migraine
with SPG stimulation
Studies on the eﬀectiveness of SPG stimulation in
migraine treatment are still pending. However, assum-
ing a pivotal role of SPG in the pathogenesis and
phenotype of migraine based on above considerations,
how may we expect stimulation of the ganglion to abort
an attack? We propose two hypotheses.
SPG modulates parasympathetic
postganglionic outflow
Burstein and Jakubowski (57) have proposed that
common migraine triggers (such as stress and awaken-
ing) may activate brain areas that all project to the
SSN. The SSN then stimulates the release of parasym-
pathetic neurotransmitters VIP, nitric oxide, and acetyl
choline from meningeal terminals of SPG neurons (58).
This cascade of parasympathetic activation results in
dilation of intracranial blood vessels, PPE, and local
release of inﬂammatory molecules to activate menin-
geal nociceptors, and thereby induce the migraine head-
ache (23,57). Based on this theory of a common
descending pathway that activates meningeal nocicep-
tors, SPG neuromodulation may abort an attack by
interrupting the centrally initiated cascade of parasym-
pathetic outﬂow, possibly by depleting stored neuro-
transmitter. Inhibiting the activation of the trigeminal
aﬀerents may also cancel out triggering of the trige-
mino-autonomic reﬂex, thus hindering CAS presenta-
tion. Interestingly, Akerman et al. (64) have shown that
low-frequency stimulation of the SSN in cats leads to
ﬁring of trigeminovascular neurons in the trigeminocer-
vical complex as well as increased blood ﬂow to the
lacrimal sac, mediated by increased parasympathetic
output. This response emphasizes the prospect that
high-frequency SPG stimulation may decrease para-
sympathetic output, thereby inhibiting the excitatory
action on trigeminal nociceptors to alleviate migraine
pain and associated autonomic symptoms.
Tepper et al. (65) applied SPG stimulation to treat
intractable migraine (n¼ 11), where two patients
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three experienced pain reduction. While these results
may not be conclusive as to the beneﬁcial potential of
this treatment, the authors conclude that lack of head-
ache relief appears linked to suboptimal lead place-
ment, poor physiological response, and diagnosis of
medication-overuse headache. Ansarinia et al. (66)
achieved more promising results in the treatment of
acute CH, where complete resolution was obtained in
11 out of 18 attacks, and> 50% relief in an additional
four attacks. Most recently, Schoenen et al. (67) pub-
lished results of the randomized, sham-controlled path-
way CH-1 study of SPG stimulation for chronic CH
(CCH) treatment. This study included in total 28 eli-
gible patients; 67.1% of attacks were relieved in 64% of
patients and 43% had a 50% reduction in attack fre-
quency. Acute pain relief as well as reduction in attack
frequency were reported in 7% of patients. The authors
concluded that SPG stimulation is an eﬀective novel
therapy for CCH suﬀerers, with a bimodal beneﬁt:
acute pain relief and attack prevention. The acute
pain relief may arise because of SPG stimulation
acting on the trigeminal nociceptive system via an
inhibitory information block from the SPG to the
target organs of CH (66). The prophylactic eﬀect, how-
ever, may stem from antidromic hypothalamic modu-
lation, the hypothalamus being a main contributor to
the pathophysiology of CH (68–70). Anatomically,
hypothalamus modulation through SPG stimulation is
feasible as the ganglion receives parasympathetic ﬁbers
from the SSN, which in turn receives input from the
hypothalamus.
SPG modulates sensory processing in trigeminal
nucleus caudalis (TNC)
Could SPG stimulation result in pain relief due to
modulation of sensory processing in the TNC rather
than blockade of SPG parasympathetic output? While
SPG stimulation has shown to produce mild residual
facial pain in the maxillary distribution area (66),
migraine headache is experienced in the innervation
area of the ophthalmic nerve. Therefore, any pain
relief due to sensory processing would presumably
stem from a central modulation based on the conver-
gence of trigeminal aﬀerents in the TNC (71), an anti-
nociceptive mechanism similar to that of ONS (72), as
occipital nerve ﬁbers also converge centrally with aﬀer-
ents from the ﬁrst trigeminal branch.
In the parallel discussion of how occipital nerve
stimulation (ONS) may be eﬀective in treating CH
patients, Magis et al. (69,73) suggest that ONS works
by inducing slow neuromodulatory changes in central
pain processing structures, rather than by sensory pro-
cessing in the TNC. A positron-emission tomography
(PET) study performed in CH patients treated with
ONS showed that hypermetabolism in the pain-
associated areas (e.g. cingulate gyrus and midbrain)
prior to treatment normalized over three to six months
with ONS, while hypermetabolism in the hypothalamus
remained unchanged (70). These results suggest that
ONS acts symptomatically rather than causally, as the
study did not prove ONS to alter the activity of the
hypothalamus. If we assume that the same mode of
action applies to migraineurs, SPG stimulation might
act symptomatically because of neuromodulatory
changes in central pain processing structures, while not
aﬀecting the actual pathophysiology of migraine.
Assuming that our hypothesis of migraine pain alle-
viation through sensory modulation in TNC is viable,
we cannot entirely exclude the consideration that tri-
geminal neurostimulation in itself may be equally
eﬀective, thus not necessarily implicating the SPG. In
support of this, a recent randomized controlled trial
shows that supraorbital transcutaneous stimulation is
eﬀective in preventing migraine (74). Finally, because of
the close spatial connection between the SPG and sur-
rounding structures, focal stimulation of the SPG may
prove challenging. Therefore, parasympathetic and sen-
sory ﬁbers in the ganglion are possibly targeted simul-
taneously during SPG stimulation, and our proposed
hypotheses of parasympathetic respective sensory
modulation may not be mutually exclusive, but rather
additive.
Methodological limitations of existing
studies on autonomic dysfunction
in migraine
There is currently no scientiﬁc consensus on the degree
and character of autonomic dysfunction in migraineurs.
The results of applied studies are largely contradictory
(Table 2), even when comparing studies employing
identical tests, indicating that objective veriﬁcation of
ANS dysfunction is complex.
Studies have largely investigatedpatients exhibiting the
large spectrum of autonomic features (including nausea,
vomiting, diarrhea, etc) rather thanCASspeciﬁcally, lead-
ing to the questionwhether these tests have actually inves-
tigated the factor relevant to our focus, i.e. cranial
autonomicdysfunctionasmigrainepain andCASprecipi-
tator? Only two studies employ tests that speciﬁcally
examine the cranial autonomic function, i.e. the trige-
mino-parasympathetic reﬂex and pupillometry test.
Cardiovascular tests are more widely applied, but is car-
diovascular dysfunction necessarily indicative of overall
autonomic dysfunction, or indeed cranial dysfunction?
We need a reﬁned test battery to speciﬁcally investi-
gate cranial autonomic function in migraineurs to
fully assess the possible role of SPG stimulation in
migraine treatment. Also, more optimal patient
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stratiﬁcation is warranted to provide detailed informa-
tion on the degree of autonomic dysfunction and to
increase the speciﬁcity of applied tests.
Future perspective
Based on anatomic and physiological considerations,
parasympathetic nervous system involvement in
migraine pathophysiology is probable. Therefore, inter-
rupting the autonomic pathway that possibly both gen-
erates the pain of migraine and mediates CAS via the
trigemino-parasympathetic reﬂex may serve to inhibit
the initiation and presentation of this debilitating
primary headache.
We suggest a possible role for SPG stimulation in the
treatment of migraine, considering the central role of
SPG in mediating parasympathetic outﬂow to struc-
tures of the cranium involved in migraine with CAS,
particularly the cranial vessels, meninges, lacrimal
gland, nasal mucosa, and conjunctiva. We hypothesize
that SPG stimulation may work by either of two mech-
anisms to terminate migraine; 1) interrupting parasym-
pathetic outﬂow of the ganglion by interfering with
preganglionic SSN to SPG eﬀerents or postganglionic
outﬂow, or 2) modulating the sensory processing in
TNC, perhaps by way of slow neuromodulatory
changes to the pain processing structures of the brain
stem. Admittedly, since attack-associated autonomic
symptoms are more dramatic in the trigeminal auto-
nomic cephalalgias than in migraine and because out-
come in the proof-of-concept study of SPG stimulation
during migraine attacks by Tepper et al. (65) was less
favorable than that observed with the same method in
CH attacks, one might expect migraineurs to beneﬁt
less from SPG stimulation than CH patients.
However, we should be cautious in drawing any ﬁrm
conclusions based on studies with small sample sizes.
Also, there may be a tendency to overlook autonomic
symptoms in migraineurs as they are often not spon-
taneously reported by the patients.
CAS presentation is not a prerequisite for SPG
stimulation, as we anticipate analgesia attributed to
the eﬀects of neuromodulation. Such pain relief has
been suggested to stem from activation of aﬀerent Ab
ﬁbers and gate control in the spinal cord (75) or from a
descending supraspinal control from the periaqueductal
gray matter and rostroventromedial medulla (76).
Additional clinical trials are needed to fully uncover
whether optimal treatment is achieved by stimulating
uni- or bilaterally. Prominent symptom and pain lat-
erality may indicate unilateral stimulation, while side-
shift occurrence (68,77) may advocate for bilateral
stimulation.
A possible role of the hypothalamus in migraine
onset is supported by the premonitory symptoms
experienced prior to attack onset, the nature of typical
migraine triggers (including stress regulation, sleep,
food intake, and hormonal changes) and the neuronal
connection between hypothalamus and SSN (57,78,79).
Moreover, in a recent imaging study hypothalamic acti-
vation was demonstrated during the premonitory phase
of migraine attacks (80). Could SPG stimulation then
work antidromically to modulate hypothalamic output,
thereby preventing the autonomic cascade that initiates
migraine? At present, there are no data supporting a
hypothalamic eﬀect of SPG stimulation. However, this
thesis may be worth investigating further, seeing as the
application of neuromodulation to aﬀect upstream
components is no new therapeutic concept. Namely,
vagus nerve stimulation is widely recognized as an
eﬀective treatment of intractable epilepsy, approved
by the United States Food and Drug Administration
(FDA) in 1997 (81–83).
Overall, more reﬁned studies on autonomic dysfunc-
tion in migraineurs will aid in assessing the therapeutic
relevance of SPG neurostimulation. Also, future rando-
mized clinical trials using SPG stimulation to treat
migraine are warranted to conclude on its true promise
as treatment modality as well as to uncover how exactly
a beneﬁcial eﬀect is exerted.
Clinical implications
. Migraine symptoms including parasympathetic manifestations of lacrimation, nasal congestion, conjunc-
tival injection, and parasympathetic activity may also contribute to the pain of migraineurs.
. The sphenopalatine ganglion (SPG) is the largest extracranial parasympathetic ganglion of the head, inner-
vating structures involved in migraine with cephalic autonomic symptoms.
. Because of the association between innervation organs of the SPG and the clinical presentation of migraine,
we suggest the prospect of treating migraine with SPG neurostimulation.
. Two possible mechanisms of action are: 1) interrupting the post-ganglionic parasympathetic outﬂow
to inhibit the pain and cephalic autonomic symptoms, and 2) modulating the sensory processing in the
trigeminal nucleus caudalis.
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